Evidence Hub

Transthyretin Cardiac Amyloidosis in a Safety-Net Hospital: A Case Series of 10 Afro-Caribbean Patients

Keston Rattan, Elizabeth L. Allison, Wayne-Andrew Palmer, Inna Bukharovich

JACC Case Reports, 2026

Abstract

Transthyretin cardiac amyloidosis (ATTR-CA) is profoundly underdiagnosed in Afro-Caribbean populations despite the high prevalence of the Val122Ile (V142Ile) variant (approximately 3.4% carrier frequency among self-identified Black individuals in the United States). This case series describes 10 Afro-Caribbean patients diagnosed with ATTR-CA at a safety-net hospital. Seven patients presented with heart failure symptoms, while 3 presented with alternative manifestations including syncope with high-degree atrioventricular block and pericardial tamponade. The mean age was 75 ± 8 years, with 80% male predominance. All patients demonstrated a positive 99mTc-PYP scan, and cardiac magnetic resonance imaging was performed in 20%. Among patients with completed genetic testing, 50% had the Val122Ile variant, and 50% had the wild-type ATTR. Atrial fibrillation was present in 50%, and 30% required permanent pacemaker implantation for symptomatic bradycardia. This series demonstrates that ATTR-CA can be effectively diagnosed in resource-limited safety-net hospitals, emphasizing these institutions' critical role in reducing health disparities.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free